NCT02634346 - A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) | Biotech Hunter

Enrollment

403

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

May 25, 2017

Study Completion Date

June 7, 2017

Conditions

Schizophrenia

Interventions

DRUG

ALK3831

Daily dosing

DRUG

Olanzapine

Daily dosing

DRUG

Placebo

Daily dosing

Trial Locations (31)

20016

Alkermes Investigational Site, Washington D.C.

33161

Alkermes Investigational Site, North Miami

45417

Alkermes Investigational Site, Dayton

60640

Alkermes Investigational Site, Chicago

63141

Alkermes Investigational Site, St Louis

72211

Alkermes Investigational Site, Little Rock

72764

Alkermes Investigational Site, Springdale

75243

Alkermes Investigational Site, Dallas

89102

Alkermes Investigational Site, Las Vegas

90230

Alkermes Investigational Site, Culver City

90822

Alkermes Investigational Site, Long Beach

91945

Alkermes Investigational Site, Lemon Grove

92103

Alkermes Investigational Site, San Diego

92845

Alkermes Investigational Site, Garden Grove

92868

Alkermes Investigational Site, Orange

08053

Alkermes Investigational Site, Marlton

Unknown

Alkermes Investigational Site, Burgas

Alkermes Investigational Site, Kazanlak

Alkermes Investigational Site, Lovech

Alkermes Investigational Site, Novi Iskar

Alkermes Investigational Site, Plovdiv

Alkermes Investigational Site, Veliko Tarnovo

Alkermes Investigational Site, Vratsa

Alkermes Investigational Site, Belgrade

Alkermes Investigational Site, Kragujevac

Alkermes Investigational Site, Novi Kneževac

Alkermes Investigational Site, Cherkasy

Alkermes Investigational Site, Kherson

Alkermes Investigational Site, Kiev

Alkermes Investigational Site, Lviv

Alkermes Investigational Site, Vinnytsia